

MATRIX

23 May 2011

MATRIX

Placing to raise £13 million for EKF Diagnostics Holdings plc

Matrix Group's Investment Banking business announces today that it has raised £13 million for EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, through a placing of new ordinary shares in the Company, at a price of 20 pence per ordinary share.

Matrix Corporate Capital LLP is EKF Diagnostics Holdings' joint broker and placed the shares with institutional shareholders to fund the acquisition of Stanbio Laboratory L.P. and for additional working capital. Stanbio is an established 50 year old US based medical diagnostic devices distribution and manufacturing business, with a strong brand and robust product sales

Malcolm Le May, CEO of the Investment Banking business of Matrix Group, commented:

"Matrix is delighted to have acted for EKF Diagnostics Holdings on this successful £13 million fundraising in what are challenging market conditions. We are pleased that there was significant demand from blue chip institutions to take part, underlining the quality of EKF Diagnostics Holdings' management and highlighting a robust support of their strategy of building a substantial point of care diagnostics business focused primarily on the significant commercial market for diabetes testing."

Application will be made for the Placing Shares to be admitted to trading on AIM and it is expected that Admission will become effective, and dealings will commence, on 16 June 2011.

Prior to today, Matrix raised £15 million for the Company in June 2010.

For further information please contact:

Kreab Gavin Anderson

James Benjamin / Madeleine Palmstierna + 44 (0) 20 7074 1800

Matrix Group

Natasha Newman + 44 (0) 20 3206 7130

Notes to Editors

The Investment Banking business of Matrix Group is a client focused, advisory, capital raising and securities sales, trading and research firm in the small and mid-cap UK and pan-European space. It brings together considerable experience, knowledge and access to meet and match the strategic ambitions of growing companies and the performance needs of investing institutions. Today Matrix has a 100 strong investment banking team advising over 80 retained clients and serving the sales, trading and research needs of more than 200 institutional customers.

The Investment Banking business of Matrix has significantly increased research coverage and their team of 25 analysts now covers around 200 stocks across small, mid and large cap in these selected, focused sectors:

- Business Services & Industrial Growth
- Consumer Goods & Services
- Healthcare
- Investment Funds
- Real Estate
- Resources, Energy & Clean Tech
- Technology, Media & Telecom

The Investment Banking business is part of Matrix Group, a privately owned financial services business in the UK with around £4 billion of assets under management and around 250 professionals employed across three divisions: Asset Management, Investment Banking and Property. Since inception in 1987, Matrix has raised £18 billion of assets for investments across these business areas.

EKF Diagnostics Holdings plc (the "Group")

In July 2010, the Group completed the acquisition of EKF-diagnostic GmbH for €14.32 million and refocused its strategy to one of building a substantial point of care diagnostics business focused primarily on the significant commercial market for diabetes testing. As part of this strategy, the Group has integrated two further acquisitions, Quotient Diagnostics Limited ("Quotient"), acquired in October 2010 for a maximum total consideration of £5.41m and Argutus Medical Limited, acquired in December 2010 for £2.18 million.

The Group, with its head office in Cardiff and operations in London, Germany, Poland, Russia and Ireland, is a leading diagnostics business, focused on the development, production and distribution of analysers for the testing of glucose, lactic acid, haemoglobin, red blood cell content (haematocrit) and glycated haemoglobin ("HbA1c"). Recently, the Group has been granted SFDA approval in China for its proprietary Quo-Test HbA1c testing platform. With this approval, Quotient will be able to commence the promotion, distribution and sale of its Quo-Test HbA1c reagent kit on its testing platform in China.

Income is generated from customers located worldwide and recently the Group won significant orders for its Hemo_Control (rapid haemoglobin test) product. For example, in Peru, the Company recently won an order for 3,000 units with a value of approximately €1 million and, in Tanzania, the Company won an order for 950 units with a value of approximately €200,000 and a follow on order with a value of approximately €228,000.

The Group has strong sales representation in the European Market but only limited exposure to the US Market. The Board believes that the proposed acquisition of Stanbio represents a significant opportunity to achieve enhanced sales in the US; the largest point of care diagnostics market in the world.